AR and prostate cancer: In summary, these data reveal that blocking the transcriptional activities of both full-length AR and truncated AR-Vs with ralaniten inhibits the expression of DDR genes, cell proliferation, as well as cell survival, thereby leading to increased sensitivity of prostate cancer to radiotherapy.